The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...

Aethlon Medical receives Ethics Committee approval for Hemopurifier cancer trial in India: San Diego Saturday, September 21, 2024, 09:00 Hrs [IST] Aethlon Inc., a medical therapeu ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments ...

(Northwestern University) The FDA expanded approval of pembrolizumab (Keytruda) to include combination therapy ... (JAMA Network Open) A phase III trial of the antibody-drug conjugate patritumab ...